Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.70259 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emergence of Maribavir-Resistant Cytomegalovirus in Transplant Recipients Treated for Refractory/Resistant Cytomegalovirus Infection.
J Med Virol
February 2025
Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection.
J Pharmacokinet Pharmacodyn
December 2024
Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., 500 East Kendall Street, Cambridge, MA, 02142, USA.
Maribavir is approved for management of post-transplant cytomegalovirus (CMV) infections refractory and/or resistant to CMV therapies at a dose of 400 mg twice daily (BID). Population pharmacokinetic (PopPK) and exposure-response analyses were conducted to support the appropriateness of 400 mg BID dosing. A PopPK model was developed using non-linear mixed-effects modeling with pooled maribavir plasma concentration-time data from phase 1 and 2 studies (from 100 mg up to 1200 mg as single or repeated doses) and the phase 3 SOLSTICE study (400 mg BID).
View Article and Find Full Text PDF